RNA modified immune therapies
Our lab focuses on applying the latest state-of-the-art in oligonucleotides for immune diseases and immune cell modification. We are embedded in the clinical department of hematology/oncology and are set out the realize the rapid bed-to-bedside potential of RNA based therapies. We are currently focusing on optimizing oligonucleotide uptake and duration of effect in essential cell based therapies, such as in stem cell transplantation, donor lymphocyte infusion, CAR T cell etc.
GRT projects
Precise immunosuppression for GvHD prophylaxis and/or treatment
- RNA modified donor lymphocyte infusions
- RNA modified hematopoetic stem cell grafts
- Systemic treatment of HSCT mice (and patients) with RNA therapeutics
Aicardi Goutieres Syndrome
- LINE1 downregulation
Duration of effect of RNA therapeutics in rapidly dividing cells
GRT expertise
- siRNA, artificial miRNA, antimir, LNPs, extracellular vesicles, oligonucleotide pharmacokinetics
- RNA modified cell therapies
- hematopoetic stem cell transplantation, graft-versus-host disease
- Main GRT methods applied in the lab
- Chemically modified oligonucleotides: siRNA, artificial miRNA, antimir
- Extracellular vesicles production
- LNP production
- High throughput oligonucleotide screening
- QuantiGene assays
- Flow cytometry
- PNA assay
- Oligonucleotide pharmacokinetics in mice
- Primary immune cells
Preclinical projects in the past five years:
- Oligonucleotides pharmacokinetics
- Huntington´s disease
- Preeclampsia
- Graft-versus-host disease
- Aicardi Goutieres Syndrome
- Systemic lupus erythematosus
- T cell exhaustion
Ongoing funding:
- Max Eder Nachwuchsgruppe
- PRECISE.net - Else Kröner Fresenius Graduiertenkolleg
- Med. Fakultät Nachwuchsgruppe Plus
- Med. Fakultät Clinician Scientist